Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Invested Capital (2022 - 2025)

Axsome Therapeutics' Invested Capital history spans 4 years, with the latest figure at $208.3 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 12.12% year-over-year to $208.3 million; the TTM value through Dec 2025 reached $208.3 million, down 12.12%, while the annual FY2025 figure was $208.3 million, 12.12% down from the prior year.
  • Invested Capital for Q4 2025 was $208.3 million at Axsome Therapeutics, up from $193.7 million in the prior quarter.
  • Across five years, Invested Capital topped out at $458.8 million in Q2 2023 and bottomed at $64.7 million in Q1 2022.
  • The 4-year median for Invested Capital is $235.1 million (2024), against an average of $250.8 million.
  • The largest annual shift saw Invested Capital skyrocketed 316.34% in 2023 before it tumbled 62.65% in 2024.
  • A 4-year view of Invested Capital shows it stood at $204.6 million in 2022, then surged by 81.36% to $371.0 million in 2023, then crashed by 36.11% to $237.0 million in 2024, then decreased by 12.12% to $208.3 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Invested Capital are $208.3 million (Q4 2025), $193.7 million (Q3 2025), and $193.1 million (Q2 2025).